BioMarin Pharmaceutical (BMRN) News Today $68.73 +3.12 (+4.76%) Closing price 02/20/2025 04:00 PM EasternExtended Trading$68.72 -0.01 (-0.01%) As of 07:20 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Zacks Research Issues Positive Estimate for BMRN EarningsBioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) - Stock analysts at Zacks Research raised their Q3 2025 earnings estimates for shares of BioMarin Pharmaceutical in a report issued on Monday, February 17th. Zacks Research analyst S. Ganoria now anticipates that the biotechnology company wFebruary 21 at 6:29 AM | marketbeat.com58,400 Shares in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Purchased by Alberta Investment Management CorpAlberta Investment Management Corp acquired a new stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 58,400 shares of the bioteFebruary 21 at 4:28 AM | marketbeat.comZacks Research Issues Optimistic Outlook for BMRN EarningsFebruary 21 at 4:25 AM | americanbankingnews.comEquities Analysts Offer Predictions for BMRN Q3 EarningsFebruary 21 at 2:25 AM | americanbankingnews.comDemystifying Biomarin Pharmaceutical: Insights From 8 Analyst ReviewsFebruary 20 at 8:55 PM | benzinga.comBioMarin Pharmaceutical (BMRN) Receives a Buy from Piper SandlerFebruary 20 at 8:55 PM | markets.businessinsider.comBioMarin Pharmaceutical Inc (BMRN) Reports Strong 2024 Financial Results and Sets Ambitious ...February 20 at 8:30 PM | gurufocus.comWhy BioMarin Pharmaceutical Stock Zoomed Almost 5% Higher TodayFebruary 20 at 6:34 PM | fool.comBioMarin Pharmaceutical (NASDAQ:BMRN) Releases FY 2025 Earnings GuidanceBioMarin Pharmaceutical (NASDAQ:BMRN) updated its FY 2025 earnings guidance. The company provided EPS guidance of 4.200-4.400 for the period, compared to the consensus estimate of 4.160. The company also issued revenue guidance of $3.1 billionillion-$3.2 billionillion, compared to the consensus estimate of $3.1 billionillion.February 20 at 5:29 PM | marketbeat.comBioMarin Pharmaceutical (NASDAQ:BMRN) Releases Quarterly Earnings Results, Beats Estimates By $0.18 EPSBioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) announced its earnings results on Wednesday. The biotechnology company reported $0.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.54 by $0.18. BioMarin Pharmaceutical had a net margin of 11.71% and a return on equity of 8.53%.February 20 at 5:13 PM | marketbeat.comWedbush Remains a Buy on BioMarin Pharmaceutical (BMRN)February 20 at 3:54 PM | markets.businessinsider.comWhy BioMarin Pharmaceutical (BMRN) Stock Is Trading Up TodayFebruary 20 at 3:54 PM | msn.comBioMarin Pharma Shares Rise After Higher 4Q, Upbeat OutlookFebruary 20 at 10:53 AM | marketwatch.comBioMarin price target raised to $80 from $78 at ScotiabankFebruary 20 at 10:53 AM | markets.businessinsider.comBioMarin Pharmaceutical (BMRN) Gets a Buy from BarclaysFebruary 20 at 10:53 AM | markets.businessinsider.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q4 2024 Earnings Call TranscriptFebruary 20 at 10:53 AM | msn.comBioMarin Pharmaceutical (NASDAQ:BMRN) Reports Bullish Q4, Stock SoarsFebruary 20 at 10:53 AM | finance.yahoo.comZacks Research Analysts Boost Earnings Estimates for BMRNBioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) - Investment analysts at Zacks Research upped their Q4 2025 EPS estimates for BioMarin Pharmaceutical in a research note issued to investors on Monday, February 17th. Zacks Research analyst S. Ganoria now expects that the biotechnology compFebruary 20 at 7:24 AM | marketbeat.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Bought by New York State Teachers Retirement SystemNew York State Teachers Retirement System grew its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 4.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 106,138 shares of the biotechnFebruary 20 at 3:27 AM | marketbeat.comBioMarin Pharmaceutical (BMRN) Projected to Post Quarterly Earnings on ThursdayBioMarin Pharmaceutical (NASDAQ:BMRN) will be releasing earnings before the market opens on Thursday, February 27. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=662720)February 20 at 2:16 AM | marketbeat.comQ4 2024 BioMarin Pharmaceutical Inc Earnings Call TranscriptFebruary 20 at 12:28 AM | gurufocus.comBioMarin Pharmaceutical Inc. (BMRN) Q4 2024 Earnings Call TranscriptFebruary 19 at 9:01 PM | seekingalpha.comBioMarin Pharmaceutical Inc. 2024 Q4 - Results - Earnings Call PresentationFebruary 19 at 5:15 PM | seekingalpha.comBioMarin: EPS Surges Past ExpectationsFebruary 19 at 5:05 PM | fool.comBioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 GuidanceFebruary 19 at 4:05 PM | prnewswire.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Sold by Rice Hall James & Associates LLCRice Hall James & Associates LLC decreased its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 43.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,791 shares of the biotechnFebruary 19 at 5:30 AM | marketbeat.comRhumbline Advisers Buys 11,025 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Rhumbline Advisers increased its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 2.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 556,255 shares of the biotechnology company's sFebruary 19 at 4:03 AM | marketbeat.comWhat To Expect From BioMarin Pharmaceutical’s (BMRN) Q4 EarningsFebruary 18 at 7:05 PM | msn.comVan ECK Associates Corp Sells 29,813 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Van ECK Associates Corp decreased its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 22.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 102,319 shares of the biotecFebruary 18 at 3:26 AM | marketbeat.comSavant Capital LLC Has $1.90 Million Stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Savant Capital LLC grew its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 106.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 28,936 shares of the biotechnology company'sFebruary 14, 2025 | marketbeat.comEntropy Technologies LP Invests $500,000 in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Entropy Technologies LP acquired a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 7,604 shares of the biotechnFebruary 13, 2025 | marketbeat.comState of Alaska Department of Revenue Cuts Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)State of Alaska Department of Revenue decreased its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 25.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,730 shares ofFebruary 13, 2025 | marketbeat.comStockNews.com Upgrades BioMarin Pharmaceutical (NASDAQ:BMRN) to Strong-BuyFebruary 13, 2025 | americanbankingnews.comBioMarin Pharmaceutical (BMRN) Projected to Post Earnings on WednesdayBioMarin Pharmaceutical (NASDAQ:BMRN) will be releasing earnings after the market closes on Wednesday, February 19. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=662720)February 12, 2025 | marketbeat.comSumitomo Mitsui Trust Group Inc. Boosts Stock Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Sumitomo Mitsui Trust Group Inc. lifted its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 3.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 470,043 shares of the biotechnology company'February 12, 2025 | marketbeat.comBleakley Financial Group LLC Invests $330,000 in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Bleakley Financial Group LLC purchased a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 5,014 shares of the biotechFebruary 12, 2025 | marketbeat.comBioMarin Pharmaceutical (NASDAQ:BMRN) Stock Rating Upgraded by StockNews.comStockNews.com raised BioMarin Pharmaceutical from a "buy" rating to a "strong-buy" rating in a report on Tuesday.February 11, 2025 | marketbeat.comBrokerages Set BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Price Target at $94.20February 11, 2025 | americanbankingnews.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Holdings Decreased by Janney Montgomery Scott LLCJanney Montgomery Scott LLC trimmed its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 34.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,671 shares of the biotechnology company's stock after seFebruary 10, 2025 | marketbeat.comStoneridge Investment Partners LLC Buys 6,355 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Stoneridge Investment Partners LLC lifted its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 151.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 10,545 shares of the biotechnology comFebruary 9, 2025 | marketbeat.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Position Trimmed by Lecap Asset Management Ltd.Lecap Asset Management Ltd. reduced its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 40.8% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 8,492 shares of the biotechnology company's stock after selling 5,863 sharFebruary 9, 2025 | marketbeat.comWhy BioMarin Pharmaceutical Inc. (BMRN) Is Among the Best Healthcare Stocks To Buy According to AnalystsFebruary 8, 2025 | msn.comAdvisors Preferred LLC Acquires New Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Advisors Preferred LLC bought a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The fund bought 14,329 shares of the biotechnology company's stock, valued at approximately $95February 8, 2025 | marketbeat.comEULAV Asset Management Sells 23,000 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)EULAV Asset Management cut its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 17.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 108,000 shares of the biotechnology company's stock afterFebruary 8, 2025 | marketbeat.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives Average Recommendation of "Moderate Buy" from AnalystsShares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Get Free Report) have been given an average recommendation of "Moderate Buy" by the twenty-three research firms that are currently covering the firm, MarketBeat reports. Seven analysts have rated the stock with a hold rating, fifteen have assignFebruary 8, 2025 | marketbeat.comBioMarin Pharmaceutical Inc. Announces Upcoming Financial Results Conference CallFebruary 5, 2025 | gurufocus.comBioMarin to Host Fourth Quarter and Full-Year 2024 Financial Results Conference Call and Webcast on Wednesday, February 19, 2025, at 4:30pm ETFebruary 5, 2025 | prnewswire.comabrdn plc Acquires 168,121 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)abrdn plc increased its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 31.9% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 695,802 shares of the biotechnology company's stock after aFebruary 5, 2025 | marketbeat.comMediolanum International Funds Ltd Makes New Investment in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Mediolanum International Funds Ltd bought a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 18,939 shares of the biotechnFebruary 3, 2025 | marketbeat.comRobeco Institutional Asset Management B.V. Trims Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Robeco Institutional Asset Management B.V. cut its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 58.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 86,574 shares of the biFebruary 3, 2025 | marketbeat.com Get BioMarin Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address BMRN Media Mentions By Week BMRN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BMRN News Sentiment▼0.760.60▲Average Medical News Sentiment BMRN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BMRN Articles This Week▼4410▲BMRN Articles Average Week Get BioMarin Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ALNY News Today BIIB News Today UTHR News Today INCY News Today NBIX News Today EXEL News Today EXAS News Today RGEN News Today HALO News Today MDGL News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BMRN) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredNvidia > DeepSeekEveryone's getting it all wrong … Sure, DeepSeek's reveal caused AI stocks to tumble … But, in the long ...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioMarin Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioMarin Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
